Vectura Group PLC (VEC) Given Buy Rating at Shore Capital
VEC has been the subject of several other reports. Numis Securities Ltd reiterated a buy rating and set a GBX 205 ($2.70) price objective on shares of Vectura Group PLC in a research note on Thursday, October 5th. Peel Hunt restated a hold rating and set a GBX 160 ($2.10) target price on shares of Vectura Group PLC in a report on Tuesday, October 31st. Panmure Gordon restated a buy rating on shares of Vectura Group PLC in a report on Wednesday, August 30th. J P Morgan Chase & Co decreased their target price on Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an overweight rating on the stock in a report on Thursday, September 21st. Finally, Citigroup Inc. decreased their target price on Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating on the stock in a report on Monday, September 18th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. Vectura Group PLC currently has an average rating of Buy and a consensus price target of GBX 189.67 ($2.49).
Vectura Group PLC (VEC) traded down GBX 0.15 ($0.00) during trading on Thursday, reaching GBX 90.55 ($1.19). The company’s stock had a trading volume of 2,724,522 shares, compared to its average volume of 1,560,000. Vectura Group PLC has a 1 year low of GBX 86.50 ($1.14) and a 1 year high of GBX 166.97 ($2.20).
TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.watchlistnews.com/vectura-group-plc-vec-given-buy-rating-at-shore-capital/1696560.html.
In other news, insider Andrew Derodra purchased 82,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The shares were acquired at an average price of GBX 90 ($1.18) per share, for a total transaction of £73,800 ($97,066.95). Also, insider Bruno Angelici purchased 70,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was purchased at an average price of GBX 99 ($1.30) per share, for a total transaction of £69,300 ($91,148.23). In the last quarter, insiders purchased 152,456 shares of company stock worth $14,354,880.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.